Progyny Q4 revenue rises 6.7%, beats expectations

Overview

• Women's health solutions firm's Q4 revenue up 6.7%, beating analyst expectations

• Adjusted EBITDA for Q4 increased 8.2%, beating analyst estimates

• Company repurchased 6.5 mln shares, returning $160 mln to shareholders

Outlook

• Progyny projects 2026 revenue between $1.355 bln and $1.405 bln

• Company expects 2026 net income of $95.4 mln to $106.1 mln

• Progyny anticipates first-quarter 2026 revenue of $319 mln to $332 mln

Result Drivers

• FERTILITY SERVICES - Fertility benefit services revenue increased 11% from Q4 2024

• MARGIN IMPROVEMENT - Gross margin rose to 24.1% due to efficiencies in care management services

Company press release: ID:nGNXbX6bf1

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the managed healthcare peer group is "buy"

• Wall Street's median 12-month price target for Progyny Inc is $30.00, about 40.6% above its February 25 closing price of $21.33

• The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.